Patents Assigned to Rosetta-Genomics
-
Patent number: 7777022Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 26, 2004Date of Patent: August 17, 2010Assignee: Rosetta Genomics, Ltd.Inventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7759478Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: August 29, 2003Date of Patent: July 20, 2010Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7709616Abstract: Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.Type: GrantFiled: May 16, 2005Date of Patent: May 4, 2010Assignee: Rosetta Genomics Inc.Inventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 7696342Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: August 27, 2003Date of Patent: April 13, 2010Assignee: Rosetta Genomics, Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7696334Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: August 28, 2003Date of Patent: April 13, 2010Assignee: Rosetta Genomics, Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7687616Abstract: The present invention describes a novel approach whereby small molecules may be used to modulate activity of microRNA and GAM oligonucleotides. This mode of therapy allows inter alia up regulation of a disease-related target gene of novel GAM oligonucleotides of the present invention, by countering the activity of a GAM oligonucleotides which naturally inhibits expression of that target gene. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: May 14, 2004Date of Patent: March 30, 2010Assignee: Rosetta Genomics LtdInventors: Itzhak Bentwich, Amir Avniel
-
Patent number: 7655785Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 15454 GAM precursors oligonucleotides, and 681 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: April 2, 2004Date of Patent: February 2, 2010Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7642348Abstract: Described herein are novel polynucleotides associated with prostate cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of prostate cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.Type: GrantFiled: May 8, 2006Date of Patent: January 5, 2010Assignee: Rosetta Genomics LtdInventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Patent number: 7618814Abstract: The present invention relates to a first group of novel genes, here identified as genomic address messenger or GAM genes, and a second group of novel operon-like genes, here identified as genomic record or GR genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 8607 GAM genes, and 1096 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: November 16, 2003Date of Patent: November 17, 2009Assignee: Rosetta Genomics Ltd.Inventor: Itzhak Bentwich
-
Patent number: 7592441Abstract: Described herein are novel polynucleotides associated with liver cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of liver cancer. Also described herein are methods that can be used to identify modulators of the disease-associated polynucleotides. Also described herein are methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and Microarray analysis.Type: GrantFiled: May 4, 2006Date of Patent: September 22, 2009Assignee: Rosetta Genomics LtdInventors: Itzhak Bentwich, Amir Avniel, Yael Karov, Ranit Aharonov
-
Publication number: 20080318210Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 15484 GAM precursors oligonucleotides, and 699 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: ApplicationFiled: April 2, 2004Publication date: December 25, 2008Applicant: ROSETTA GENOMICSInventor: Itzhak Bentwich
-
Publication number: 20080188428Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an operon-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: ApplicationFiled: October 30, 2003Publication date: August 7, 2008Applicant: Rosetta GenomicsInventor: Itzhak Bentwich
-
Patent number: 7250496Abstract: The present invention relates to a first group of novel genes, here identified as “genomic address messenger” or “GAM” genes, and a second group of novel operon-like genes, here identified as “genomic record” or “GR” genes. GAM genes selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 20600 GAM genes, and 6635 GR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM and GR genes and specific functions and utilities thereof, for detecting expression of GAM and GR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: GrantFiled: December 6, 2002Date of Patent: July 31, 2007Assignee: Rosetta Genomics Ltd.Inventor: Isaac Bentwich
-
Patent number: 7217807Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: GrantFiled: August 28, 2003Date of Patent: May 15, 2007Assignee: Rosetta Genomics LtdInventor: Itzhak Bentwich
-
Publication number: 20070077553Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “Viral genomic record” or “VGR genes”. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. VGR genes encode an “operon”-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: ApplicationFiled: October 30, 2003Publication date: April 5, 2007Applicant: ROSETTA GENOMICSInventor: Itzhak Bentwich
-
Publication number: 20070042380Abstract: The present invention relates to a first group of novel oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 122,764 GAM oligonucleotides and their respective precursors, and 18602 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: ApplicationFiled: May 14, 2004Publication date: February 22, 2007Applicant: ROSETTA GENOMICSInventors: Itzhak Bentwich, Amir Avniel
-
Publication number: 20070042381Abstract: The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 1,655 viral and 105,537 human GAM precursor oligonucleotides, and 190 viral and 14,813 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: ApplicationFiled: May 26, 2004Publication date: February 22, 2007Applicant: Rosetta GenomicsInventors: Itzhak Bentwich, Amir Avniel
-
Publication number: 20070042982Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various bacterial diseases. Nucleic acid molecules are provided respectively encoding 6444 GAM precursors oligonucleotides, and 726 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: ApplicationFiled: April 2, 2004Publication date: February 22, 2007Applicant: ROSETTA GENOMICSInventor: Itzhak Bentwich
-
Publication number: 20070031843Abstract: The present invention relates to a first group of novel bacterial and human associated oligonucleotides, here identified as “Genomic Address Messenger” or “GAM” oligonucleotide, and a second group of novel operon-like bacterial and human polynucleotides, here identified as “Genomic Record” or “GR” polynucleotide. GAM oligonucleotides selectively inhibit translation of known “target” genes, many of which are known to be involved in various bacterial infections. Nucleic acid molecules are provided respectively encoding 21,916 bacterial and 6,100 human GAM precursor oligonucleotides, and 6,056 bacterial and 430 human GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.Type: ApplicationFiled: May 24, 2004Publication date: February 8, 2007Applicant: ROSETTA GENOMICSInventors: Itzhak Bentwich, Amir Avniel
-
Publication number: 20070031823Abstract: The present invention relates to a group of novel viral RNA regulatory genes, here identified as “viral genomic address messenger genes” or “VGAM genes”, and as “genomic record” or “GR” genes. VGAM genes selectively inhibit translation of known host target genes, and are believed to represent a novel pervasive viral attack mechanism. GR genes encode an operon-like cluster of VGAM genes. VGAM and viral GR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.Type: ApplicationFiled: August 28, 2003Publication date: February 8, 2007Applicant: ROSETTA GENOMICSInventor: Itzhak Bentwich